A5043065014- Ovarian cancer diagnosis and treatment
- Cancer Genomics and Diagnostics
- Cytokine Signaling Pathways and Interactions
- Endometrial and Cervical Cancer Treatments
- Bladder and Urothelial Cancer Treatments
- Genetic factors in colorectal cancer
- Cancer Mechanisms and Therapy
- BRCA gene mutations in cancer
- PARP inhibition in cancer therapy
- Sarcoma Diagnosis and Treatment
- Renal cell carcinoma treatment
- Monoclonal and Polyclonal Antibodies Research
- Uterine Myomas and Treatments
- Colorectal and Anal Carcinomas
- Cancer Immunotherapy and Biomarkers
- Intraperitoneal and Appendiceal Malignancies
- Economic and Financial Impacts of Cancer
- Anesthesia and Pain Management
- Chronic Lymphocytic Leukemia Research
- Cervical Cancer and HPV Research
- Lung Cancer Treatments and Mutations
- Cancer Research and Treatments
- Cell Adhesion Molecules Research
- Renal and related cancers
- Synthesis and biological activity
West Cancer Center
2017-2025
Natera (United States)
2022-2025
University of Tennessee at Knoxville
2012-2020
University of Tennessee Health Science Center
2011-2019
St. Jude Children's Research Hospital
2019
University Hospitals Plymouth NHS Trust
2019
The Ohio State University Wexner Medical Center
2013-2018
The Ohio State University
2014-2018
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
2015-2016
Ohio University
2015
Epithelial ovarian cancer is the leading cause of death from gynecologic in United States, with less than half patients living >5 years diagnosis. A major challenge treating that most have advanced disease at initial The best outcomes are observed whose primary treatment includes complete resection all visible plus combination platinum-based chemotherapy. Research efforts focused on neoadjuvant treatments may improve resectability, as well systemic therapies providing improved long-term...
Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy. We examined utility of circulating tumor DNA (ctDNA) as a prognostic biomarker for EOC by assessing its relationship with patient outcome and CA-125, pre-surgically during post-treatment surveillance.
Abstract Purpose: To investigate whether circulating tumor DNA (ctDNA) assessment in patients with muscle-invasive bladder cancer predicts treatment response and provides early detection of metastatic disease. Experimental Design: We present full follow-up results (median follow-up: 68 months) from a previously described cohort neoadjuvant chemotherapy (NAC)-treated who underwent longitudinal ctDNA testing (712 plasma samples). In addition, we performed evaluation 153 samples collected...
IntroductionAmong uterine malignancies, endometrial cancer (EC) is the most common of female reproductive tract. Traditionally, risk stratification in EC determined by standard clinicopathological factors. Although circulating tumor DNA (ctDNA) has emerged as a prognostic biomarker various its clinical validity remains to be established.MethodsIn this analysis real-world data, 267 plasma samples from 101 patients with stage I were analyzed using tumor-informed ctDNA assay (Signatera™ bespoke...
Abstract Background LIGHT (oLaparib In HRD‐Grouped Tumor types; NCT02983799) prospectively evaluated olaparib treatment in patients with platinum‐sensitive relapsed ovarian cancer (PSROC) assigned to cohorts by known BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: germline BRCAm (gBRCAm), somatic (sBRCAm), HRD‐positive non‐BRCAm, HRD‐negative. At the primary analysis, demonstrated activity across all cohorts, greatest efficacy terms of objective response rate...
STAT3 is well corroborated preclinically as a cancer therapeutic target, but tractable translational strategies for its blockade by small molecule inhibitors have remained elusive. In this study, we report the development of novel class bifunctional inhibitors, based on conjugation diarylidenyl-piperidone (DAP) backbone to an N-hydroxypyrroline (-NOH) group, which exhibits minimal toxicity against normal cells and good oral bioavailability. Molecular modeling studies suggested direct...
Somatic HER2 mutations occur in ~5% of cervical cancers and are considered oncogenic associated with poor prognosis. Neratinib, an irreversible pan-HER tyrosine kinase inhibitor, is active multiple HER2-mutant cancers. SUMMIT a phase II basket trial investigating the efficacy safety neratinib solid tumors.Patients HER2-mutant, persistent, metastatic/recurrent cancer disease progression after platinum-based treatment for advanced/recurrent received oral 240 mg/day mandatory loperamide...
Objective HER2 mutations are associated with poor prognosis and detected in 3–6% of cervical cancers. Neratinib, an irreversible pan-HER tyrosine kinase inhibitor, had activity several HER2-mutant cancer types the phase 2 SUMMIT basket study. We present updated final results from cohort SUMMIT. Methods Eligible patients HER2-mutant, metastatic or recurrent progressing after platinum-based treatment for advanced/recurrent disease. Patients received neratinib 240 mg/day; loperamide was...
Despite complete resection, 20%-50% of patients with localized renal cell carcinoma (RCC) experience recurrence within 5 years. Accurate assessment prognosis in high-risk would aid improving outcomes. Here we evaluate the use circulating tumor DNA (ctDNA) RCC using banked samples and clinical data from a single institution.
Olaparib treatment resulted in significant improvement objective response rates (ORRs) and progression-free survival (PFS) over non‑platinum chemotherapy patients with BRCA1/BRCA2-mutated (BRCAm) platinum-sensitive relapsed ovarian cancer (PSROC) ≥2 prior lines of platinum-based the phase III SOLO3 study. LIGHT (NCT02983799) prospectively evaluated olaparib for PSROC known BRCAm homologous recombination deficiency (HRD) status.
Despite curative-intent radical cystectomy (RC), patients with muscle-invasive bladder cancer (MIBC) are at high risk of recurrence. Biomarkers urgently needed to refine prognostication and selection appropriate perioperative systemic therapies. Our aim was evaluate the prognostic predictive value tumor-informed circulating tumor DNA (ctDNA) results in a multicenter cohort who underwent RC.
Loss of function variants in the NF1 gene cause neurofibromatosis type 1, a genetic disorder characterized by complete penetrance, characteristic physical exam findings, and substantially increased risk for malignancy. However, our understanding is based on patients ascertained through phenotype-first approaches, which estimate prevalence at 1 3000. Leveraging genotype-first approach multiple large patient cohorts including over one million individuals, we demonstrate an unexpectedly high (1...
Background: Breast cancer is genetically and phenotypically heterogeneous, with tumor-specific alterations influencing clinical outcomes. This variability underscores the importance of accounting for factors such as genetic ancestry in genomic studies to better understand tumor biology improve patient care. However, most have focused on individuals European ancestry, leaving gaps knowledge about other ancestries. Here, we analyzed data from over 55,000 breast patients Natera’s proprietary...
Abstract Background: Gynecological cancers are a diverse set of malignancies, each with distinct genomic alterations that influence tumorigenesis and disease progression. Here, we analyzed data from endometrial, ovarian, cervical cancer patients, stratified by genetic ancestry, to assess differences in mutational landscapes. Methods: Whole-exome sequencing (WES) >8, 000 gynecological cases Natera’s proprietary Real-World Database were utilized. WES was performed on tumor tissues for...
Circulating tumor DNA (ctDNA) detection in blood has emerged as a prognostic and predictive biomarker demonstrating improved assessment of treatment response patients receiving immune checkpoint inhibitors (ICIs). Here, we performed pilot study to support the role ctDNA for longitudinal monitoring with advanced genitourinary (GU) malignancies ICIs.Patients histologically confirmed GU were prospectively enrolled. All eligible received ICI at least 12 weeks, followed by serial collection...
PURPOSE Tumor-informed circulating tumor DNA (ctDNA) has shown promise as a biomarker for treatment response monitoring (TRM) in variety of types, with the potential to improve clinical outcomes. We evaluated ctDNA status and dynamics during surveillance part TRM outcomes both patients clear cell renal carcinoma (ccRCC) non–clear (nccRCC) treated standard-of-care immunotherapy or targeted therapy regimens. METHODS This was multicenter retrospective analysis real-world data obtained from...
This study aimed to compare outcomes of endometrial cancer (EMCA) staging in elderly patients performed either robotically or via laparotomy.A retrospective, multi-institutional chart review was conducted all robotic and laparotomy surgeries for EMCA between 2003 2009. Charts were reviewed intraoperative postoperative complications morbidities.Seven hundred forty-six women identified who had undergone laparotomy; 89 93 70 years older underwent laparotomy, respectively. Both groups similar...
In the precision medicine era, molecular testing in advanced cancer is foundational to patient management. Molecular tumor boards (MTBs) can be effective processing comprehensive genomic profiling (CGP) results and providing expert recommendations. We assessed an MTB its role a community setting. This retrospective analysis included patients with recommendations at community-based oncology practice January 2015 December 2018; exclusions were death within 60 days of and/or no metastatic...
In Brief OBJECTIVE: To identify risk factors associated with anal intraepithelial neoplasia and develop a model for predicting the likelihood of in heterosexual women. METHODS: A prospective cohort 327 patients from 2006 to 2011 biopsy-confirmed diagnosis genital (vulvar, vaginal, or cervical) underwent both cytology anoscopy. Variables significant between those without were identified using logistic regression. forward stepwise regression analysis was carried out combination variables that...
499 Background: Serum-based tumor markers (STM) (AFP, LDH, and b-hCG) used as standard of care in patients with testicular cancer lack sufficient sensitivity specificity for molecular residual disease (MRD) detection. Although circulating (ct) DNA holds promise a prognostic biomarker variety malignancies, its clinical utility has not been well characterized. This study evaluates the longitudinal ctDNA monitoring MRD detection cancer. Methods: Retrospective analysis was performed using...